Failure to Satisfy Listing Rule (Form 8-K)

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On August 18, 2026, Silexion Therapeutics Corp, a Cayman Islands exempted company (the "Company", "we", "us" or "our") received a delisting notice from the Nasdaq Listing Qualifications Department in respect of a listing deficiency relating to our non-compliance with the minimum shareholders' equity requirement for continued listing on The Nasdaq Capital Market. That delisting notice is subject to the Company's right to request an appeal of the determination before a Nasdaq Hearings Panel (a "Panel") by August 25, 2026, which the Company intends to request in a timely manner.

The listing deficiency relates to our non-compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market that are listed under the Equity Standard to maintain a minimum of $2,500,000 of shareholders' equity for continued listing. Our quarterly report on Form 10-Q for the period ended June 30, 2026 reported shareholders' equity of $44,000, and we do not currently meet any of the alternative continued listing standards of The Nasdaq Capital Market. While we believed we had restored compliance with the shareholders' equity requirement as of the August 14, 2026 filing date of that Form 10-Q, as determined on a pro forma basis as of June 30, 2026, based on our net losses subsequent to June 30, 2026 , we do not currently meet the requirement.

As previously disclosed, following a Panel decision dated September 23, 2025, we are subject to a Mandatory Hearings Panel Monitor pursuant to Nasdaq Listing Rule 5815(d)(4)(B), under which the Nasdaq Listing Qualifications Department is not permitted to grant us additional time to regain compliance with respect to any deficiency arising during the one-year monitoring period, and accordingly the Nasdaq Listing Qualifications Department Nasdaq Listing Qualifications Department issued the delisting notice to us.

As part of our strategy for our appeal, we intend to present to the Panel evidence that we have taken steps and will continue to take steps to restore and maintain compliance with the shareholders' equity requirement. There can be no assurance, however, that our appeal will be successful or that the Panel will grant us any additional time to regain compliance with that requirement. To the extent the Company's appeal is not successful, trading in the Company's ordinary shares and warrants would be suspended, and a Form 25-NSE would be filed with the Securities and Exchange Commission, which would remove the Company's ordinary shares and warrants from listing on Nasdaq.